Quarterly report · Q1
2112.TEDINET S100RJ84
Period2023-04-01 → 2023-06-30
Filed2023-08-04
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 31
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥7.8bn | 2023-04-01 → 2023-06-30 | Cons. | Net sales |
| Revenue | ¥27.9bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥6.9bn | 2022-04-01 → 2022-06-30 | Cons. | Net sales |
| Operating income | ¥315m | 2023-04-01 → 2023-06-30 | Cons. | Operating income |
| Operating income | ¥171m | 2022-04-01 → 2022-06-30 | Cons. | Operating income |
| Ordinary income | ¥1.1bn | 2023-04-01 → 2023-06-30 | Cons. | Ordinary income |
| Ordinary income | ¥731m | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥296m | 2022-04-01 → 2022-06-30 | Cons. | Ordinary income |
| Profit before tax | ¥1.1bn | 2023-04-01 → 2023-06-30 | Cons. | Income before income taxes |
| Profit before tax | ¥296m | 2022-04-01 → 2022-06-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥888m | 2023-04-01 → 2023-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥498m | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥224m | 2022-04-01 → 2022-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥888m | 2023-04-01 → 2023-06-30 | Cons. | Profit loss |
| Net income | ¥224m | 2022-04-01 → 2022-06-30 | Cons. | Profit loss |
| Total assets | ¥27.0bn | at 2023-06-30 | Cons. | Assets |
| Total assets | ¥25.9bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥25.9bn | at 2022-06-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥14.8bn | at 2023-06-30 | Cons. | Liabilities |
| Total liabilities | ¥14.8bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥12.2bn | at 2023-06-30 | Cons. | Net assets |
| Net assets / equity | ¥11.0bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥10.4bn | at 2022-06-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥1.9bn | at 2023-06-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥2.2bn | at 2023-03-31 | Cons. | Cash and deposits |
| EPS (basic) | ¥32.55 | 2023-04-01 → 2023-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥18.28 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥8.24 | 2022-04-01 → 2022-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 45.1% | at 2023-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 42.6% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 40.3% | at 2022-06-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 38
| Segment | Item | Period | Value |
|---|---|---|---|
| Otherother segments | revenue | 2023-04-01 → 2023-06-30 | ¥33m |
| Otherother segments | revenue external | 2023-04-01 → 2023-06-30 | ¥29m |
| Otherother segments | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥4m |
| Otherother segments | segment profit | 2023-04-01 → 2023-06-30 | ¥18m |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-06-30 | −¥46m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-06-30 | −¥46m |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-06-30 | −¥271m |
| jpcrp040300-q1r_E00361-000Biotechnologyreportable segment | revenue | 2023-04-01 → 2023-06-30 | ¥514m |
| jpcrp040300-q1r_E00361-000Biotechnologyreportable segment | revenue external | 2023-04-01 → 2023-06-30 | ¥479m |
| jpcrp040300-q1r_E00361-000Biotechnologyreportable segment | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥35m |
| jpcrp040300-q1r_E00361-000Biotechnologyreportable segment | segment profit | 2023-04-01 → 2023-06-30 | ¥114m |
| jpcrp040300-q1r_E00361-000Sugarreportable segment | revenue | 2023-04-01 → 2023-06-30 | ¥7.3bn |
| jpcrp040300-q1r_E00361-000Sugarreportable segment | revenue external | 2023-04-01 → 2023-06-30 | ¥7.3bn |
| jpcrp040300-q1r_E00361-000Sugarreportable segment | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥6m |
| jpcrp040300-q1r_E00361-000Sugarreportable segment | segment profit | 2023-04-01 → 2023-06-30 | ¥454m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2023-06-30 | ¥7.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2023-06-30 | ¥7.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥46m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2023-06-30 | ¥587m |
| Otherother segments | revenue | 2022-04-01 → 2022-06-30 | ¥33m |
| Otherother segments | revenue external | 2022-04-01 → 2022-06-30 | ¥29m |
| Otherother segments | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥4m |
| Otherother segments | segment profit | 2022-04-01 → 2022-06-30 | ¥16m |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-06-30 | −¥43m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-06-30 | −¥43m |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-06-30 | −¥307m |
| jpcrp040300-q1r_E00361-000Biotechnologyreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥491m |
| jpcrp040300-q1r_E00361-000Biotechnologyreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥458m |
| jpcrp040300-q1r_E00361-000Biotechnologyreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥32m |
| jpcrp040300-q1r_E00361-000Biotechnologyreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥137m |
| jpcrp040300-q1r_E00361-000Sugarreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥6.4bn |
| jpcrp040300-q1r_E00361-000Sugarreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥6.4bn |
| jpcrp040300-q1r_E00361-000Sugarreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥6m |
| jpcrp040300-q1r_E00361-000Sugarreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥325m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-06-30 | ¥6.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-06-30 | ¥6.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥43m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-06-30 | ¥479m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 353
| Item | Context | Value | Unit |
|---|---|---|---|
| Notes significant events after reporting period quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |